Enterprise Value

237.1B

Cash

19.97B

Avg Qtr Burn

N/A

Short % of Float

0.81%

Insider Ownership

0.04%

Institutional Own.

70.67%

Qtr Updated

04/2/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Update

Approved

Quarterly sales

Approved

Quarterly sales

Oxbryta (Voxelotor) Details
SCD (Sickle Cell Disease)

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

TALA + enzalutamide Details
Cancer, Prostate cancer, Castration-resistant prostate cancer

PDUFA

Approval decision

BRAFTOVI + MEKTOVI Details
Cancer, Non-small cell lung carcinoma

PDUFA

Approval decision

Elranatamab Details
Cancer, Multiple myeloma

PDUFA

Approval decision

PDUFA

Approval decision

BLA

Acceptance for review

Aztreonam-Avibactam (ATM-AVI) Details
Pneumonia, Bacterial infection, Intra-abdominal infections

NDA

Submission

Phase 3

Data readout

Phase 3

Data readout

Phase 3

Update

Troriluzole Details
Obsessive compulsive disorder

Phase 2/3

Data readout

Troriluzole Details
Alzheimer's disease

Failed

Discontinued

Failed

Discontinued

Troriluzole Details
Spinocerebellar Ataxia

Failed

Discontinued

Verdiperstat Details
Amyotrophic lateral sclerosis

Failed

Discontinued

Verdiperstat Details
Multiple System Atrophy

Failed

Discontinued